Overview

This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.

Eligibility

Inclusion Criteria:

• Adult outpatients (\>18 years old), attending HTCM PD clinic visits
• Have undergone peritoneal dialysis for at least 6 months
• Have a serum albumin level \<40 g/L
• Have a BMI of \< 25 kg/m2
• Have a malnutrition inflammation score (MIS) of mild, moderate or severe
• Agreed to follow the dietary instructions based on the randomization assignment
• Agreed to attend baseline visits and additional follow-up appointments at months 1, 3, and 6 post- randomization, either in person or via telehealth, and respond to monthly or more frequent phone calls

Exclusion Criteria:

• Have been hospitalized for the past 3 months
• Have ongoing infection/sepsis
• Has undergone surgery in the past 6 months
• Have high inflammatory diseases, malignancy, or cancer
• Have dialysis adequacy of \<1.2 Kt/V